



IFW

Attorney Docket # 5422-2

Patent

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Yi-Chao LEE et al.

Serial No.: 10/801,292

Filed: March 15, 2004

For: Methods for Identification, Assessment,
Prevention, and Therapy of Cancer

Examiner:

Group Art:

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

June 4, 2004

(Date of Deposit)

Kent H. Cheng

Name of applicant, assignee or Registered Representative

Kent H. Cheng

Signature

June 4, 2004

Date of Signature

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

S I R:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Form PTO/SB/08a. Copies of the listed documents are also enclosed.


It is respectfully requested that the above information be considered by the Examiner and that the copy of the enclosed Form PTO/SB/08a be returned indicating that such information has been considered.

In accordance with 37 C.F.R. §§1.97(g) and (h), the filing of this Information Disclosure Statement should not be construed as a representation that a search has been made or


that information cited is, or is considered to be, material to patentability as defined in §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant(s) reserve(s) the right to prove that the date of publication is in fact different.

If any fees or charges are deemed required at this time in connection with the application, the same may be charged to our Patent and Trademark Office Deposit Account No. 03-2412.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By: 
Kent H. Cheng
Reg. No. 33,849
551 Fifth Avenue, Suite 1210
New York, New York 10176
(212) 687-2770

Dated: June 4, 2004



| | | | |
|---|--|--------------------------|----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/801,292 |
| | | Filing Date | March 15, 2004 |
| | | First Named Inventor | Yi-Chao LEE |
| | | Art Unit | |
| Sheet 1 of 2 | | Examiner Name | |
| | | Attorney Docket Number | 5422-2 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind-Code ² (if known) | | | |
| | | US-2004/0002067A1 | 1/1/204 | Erlander et al. | |
| | | US-2003/0143648A1 | 7/31/03 | Cravatt et al. | |
| | | US-6,720,146 B2 | 4/13/04 | Stolk et al. | |
| | | US-6,710,170 B2 | 3/23/04 | Xu et al. | |
| | | US-6,699,664 B1 | 3/2/04 | Mitcham et al. | |
| | | US-6,613,515 B1 | 9/2/03 | Xu et al. | |
| | | US-6,468,546 B1 | 10/22/02 | Mitcham et al. | |
| | | US-6,617,109 B1 | 9/9/03 | Xu et al. | |
| | | US-6,468,758 B1 | 10/22/02 | Benson et al. | |
| | | US-6,528,253 B1 | 3/4/03 | Mitcham et al. | |
| | | US-6,258,942 B1 | 7/10/01 | O'Brien et al. | |
| | | US-6,048,528 | 4/11/00 | Dunbar | |
| | | US-4,806,494 | 2/21/89 | Pastan et al. | |
| | | US-6,509,458 B1 | 1/21/03 | Afar et al. | |
| | | US-6,350,615 B1 | 2/26/02 | Kaufman et al. | |
| | | US- | | | |
| | | US- | | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|--|--------------------------------|--|---|--------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | ⁷ |
| | | Country Code ³ Number ⁴ Kind-Code ⁵ (if known) | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-9100 (1-800-786-9100) and select option 2

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | | | |
|---|------------------------|--------------------------|----------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/801,292 |
| | | Filing Date | March 15, 2004 |
| | | First Named Inventor | Yi-Chao LEE |
| | | Art Unit | |
| | | Examiner Name | |
| Sheet 2 of 2 | Attorney Docket Number | 5422-2 | |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | F. S. Collins, "Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences", PNAS, December 24, 2002, Vol. 99, No. 26, Pgs. 16899-16903. | |
| | | A. Yamashita, et al., "Characterization of Solt, a Novel SoxLZ/Sox6 Binding Protein Expressed in Adult Mouse Testis", FEBS Letters 481, (2000), Pgs. 147-151. | |
| | | G. Merla, et al., "Identification of Additional Transcripts in the William-Beuren Syndrome Critical Region", Hum Genet (2002) 110:429-438. | |
| | | X. Fang et al., "Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer", Annals New York Academy of Sciences, Pgs. 188-208. | |
| | | A. Tokumura, "Physiological and Pathophysiological Roles of Lysophosphatidic Acids Produced by Secretory Lysophospholipase D in Body Fluids", Biochimica et Biophysica Acta, 1982, (2002), pgs. 18. 25. | |
| | | K. Sawada, et al., "Lysophosphatidic Acid Induces Focal Adhesion Assembly Through Rho/Rho-Associated Kinase Pathway in Human Ovarian Cancer Cells", Gynecologic Oncology 87, 252-259 (2002). | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form call 1-800-PTO-0100 (1-800-776-0100) and select option 2